New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTPBMD, CYTX, HART, CAPR, ATHX, CELG, NBS, BLUE, FATEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
17:05 EDTFATEFate Therapeutics files $100M mixed securities shelf
Subscribe for More Information
07:39 EDTCELGCelgene reinstated with a Buy at BofA/Merrill
Target $112.
07:36 EDTNBSNeoStem establishes melanoma scientific advisory board ahead of Phase 3 trial
Subscribe for More Information
September 29, 2014
08:55 EDTCELGCelgene price target raised to $115 from $100 at RBC Capital
RBC Capital increased its price target on Celgene (CELG) as the firm now estimates that the company's new oral Crohn's disease drug GED-0301 will generate $1B in sales. The firm expects Celgene's stock to rise further as it predicts that Phase II data for the company's Crohn's treatment will be much better than the data for AbbVie's (ABBV) Crohn's treatment, Humira. RBC predicts that Celgene's long-term 2020 guidance will beat expectations if the company is able to reach a legal settlement with Actavis (ACT.). RBC Capital keeps an Outperform rating on Celgene.
07:26 EDTCELGInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
09:36 EDTCELGActive equity options trading on open
Subscribe for More Information
September 24, 2014
15:34 EDTCYTXCytori Therapeutics restructuring, new alignment positive, says Maxim
Subscribe for More Information
13:17 EDTCELGCelgene continues rally after FDA approval of psoriasis drug
Subscribe for More Information
07:01 EDTCELGCelgene OTEZLA to become important revenue generator, says Cantor
Subscribe for More Information
September 23, 2014
15:21 EDTCELGCelgene announces FDA approves Otezla for treating plaque psoriasis
Subscribe for More Information
10:02 EDTBLUEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:16 EDTBLUEbluebird bio initiated with a Buy at Roth Capital
Target $50.
September 22, 2014
08:12 EDTCYTXCytori sees 'modest overall revenue growth' in FY14
The company said, "Despite the impact of the cost reduction efforts, Cytori continues to anticipate modest overall revenue growth in 2014. Overall revenue growth in 2015 and 2016 will likely continue to be modest but should show a positive contribution margin beginning in 2015 based on the combination of recent expense reductions and forecasted increases in sales to Lorem Vascular and other partners, as well as through Cytori’s leaner direct sales teams in both Japan and Europe." FY14 revenue consensus $15.06M.
08:05 EDTCYTXCytori announces restructuring, cost reduction plans
Subscribe for More Information
07:21 EDTCELGEBD Group to hold a conference
Subscribe for More Information
September 18, 2014
08:10 EDTCAPRCapricor presents ALLSTAR Phase I preliminary results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use